Trends in Treatment and Survival in Older Patients Presenting with Stage IV Colorectal Cancer

Journal of Gastrointestinal Surgery

Volumn 18, Issue 2, 2014, Pages 369-377

  Vargas, Gabriela M ^a   Sheffield, Kristin M ^a   Parmar, Abhishek D ^a,b   Han, Yimei ^a   Gajjar, Aakash ^a   Brown, Kimberly M ^a   Riall, Taylor S ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer therapy; Colorectal cancer; Oncology; Stage IV cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAMPTOTHECIN; DRUG DERIVATIVE; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PLATINUM COMPLEX;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; CANCER STAGING; COLON TUMOR; FEMALE; HUMAN; MALE; MEDICARE; MORTALITY; PATHOLOGY; RECTUM TUMOR; REGISTER; SURVIVAL RATE; TIME; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MEDICARE; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RECTAL NEOPLASMS; REGISTRIES; SURVIVAL RATE; TIME FACTORS; UNITED STATES;

EID: 84895903833     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-013-2406-z     Document Type: Article

References (24)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Colorectal Cancer Detailed Guide. Available at: http://www. cancer. org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-survival-rates. Accessed 13 Mar 2013.
3. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
4. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
5. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
6. van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
7. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
8. Rinaldi F, George E, Adler AI. NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy. Lancet Oncol 2012; 13: 233-234.
9. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-2292.
10. van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30: 3499-3506.
11. Temple LK, Hsieh L, Wong WD et al. Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol 2004; 22: 3475-3484.
12. Basili G, Lorenzetti L, Biondi G et al. Colorectal cancer in the elderly. Is there a role for safe and curative surgery? ANZ J Surg 2008; 78: 466-470.
13. Konyalian VR, Rosing DK, Haukoos JS et al. The role of primary tumour resection in patients with stage IV colorectal cancer. Colorectal Dis 2007; 9: 430-437.
14. Texas Cancer Registry. Available at: http://www. dshs. state. tx. us/tcr/.
15. Surveillance Epidemiology and End Results (SEER). Available at: http://seer. cancer. gov/about/overview. html. Accessed 22 March 2013.
16. Cancer Epidemiology and Surveillance Branch, Texas Department of State Health Services, Texas Cancer Registry Division. Available at: http://www. dshs. state. tx. us/tcr/default. shtm. Accessed 6 May 2013.
17. National Cancer Institute SEER-Medicare 2013. Available at: http://healthservices. cancer. gov/seermedicare/overview/linked. html. Accessed 6 May 2013.
18. Research Data Assistance Center (ResDAC). Medicare Claims. Available at: http://www. resdac. org/cms-data/file-family/Medicare-Claims.
19. Procedure codes for SEER-Medicare Analysis. Available at: http://healthservices. cancer. gov/seermedicare/considerations/procedure_codes. html. Accessed 18 Mar 2013.
20. van Steenbergen LN, Elferink MA, Krijnen P et al. Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in The Netherlands 1989-2006. Ann Oncol 2010; 21: 2206-2212.
21. Sun E, Lakdawalla D, Reyes C et al. The determinants of recent gains in cancer survival: an analysis of the Surveillance, Epidemiology, and End Results (SEER) database. In ASCO. 2008.
22. Kopetz S, Chang GJ, Overman MJ et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: 3677-3683.
23. NCCN Clinical Practice Guidelines. Version 3. 2013 edition. 2013.
24. Cen P, Liu C, Du XL. Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer. Ann Oncol 2012; 23: 1503-1511.